TY - JOUR T1 - Genetic-Ancestry Analysis on >93,000 Individuals Undergoing Expanded Carrier Screening Reveals Limitations of Ethnicity-Based Medical Guidelines JF - medRxiv DO - 10.1101/2019.12.21.19015578 SP - 2019.12.21.19015578 AU - Kristjan E. Kaseniit AU - Imran S. Haque AU - James D. Goldberg AU - Lee P. Shulman AU - Dale Muzzey Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/27/2019.12.21.19015578.abstract N2 - Purpose Despite strong association between genetic ancestry and carrier status, current carrier-screening guidelines recommend testing for a limited set of conditions based on a patient’s self-reported ethnicity, which conflates genetic and cultural factors.Materials and Methods For 93,419 individuals undergoing a 96-gene expanded carrier screen (ECS), correspondence was assessed among carrier status, self-reported ethnicity, and a dual-component genetic ancestry (e.g., 75% African/25% European) calculated from sequencing data.Results Self-reported ethnicity was an imperfect indicator of genetic ancestry, with 9% of individuals having >50% genetic ancestry from a lineage inconsistent with self-reported ethnicity. Self-reported ethnicity-based carrier-screening guidelines are incomplete, as several conditions not included in guidelines had similarly strong correlation between carrier rate and genetic ancestry as conditions included in screening guidelines. Limitations of self-reported ethnicity led to missed carriers in at-risk populations: for 10 ECS conditions, patients with intermediate genetic ancestry backgrounds—who did not self-report the associated ethnicity—had significantly elevated carrier risk. Finally, for seven of the 16 conditions included in current screening guidelines, most carriers were not from the population the guideline aimed to serve.Conclusion To provide equitable reproductive care, guidelines should discontinue the use of ethnicity as a basis for determining which patients are appropriate for carrier screening and instead recommend pan-ethnic ECS.Competing Interest StatementKE Kaseniit, IS Haque, JD Goldberg, and D Muzzey are current or former employees of Myriad Women’s Health. IS Haque was a former employee of Freenome, Inc. and is currently employed by Recursion Pharmaceuticals.Funding StatementThis research was funded by Myriad Genetics. No external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be shared as permitted upon reasonable request to the authors. ER -